Michael Burgess, MD, PhD

Title(s)Volunteer Assistant Clinical Professor, Medicine
SchoolSchool of Medicine
AddressBristol Myers Squibb
Brisbane CA 94005
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California, San FranciscoFellowship2012Hematology and Medical Oncology
    University of California, San FranciscoResidency 2009Internal Medicine
    David Geffen School of Medicine at UCLAM.D.2007Medicine
    University of California, Los AngelesPh.D.2005Molecular Biology
    University of California, BerkeleyB.A.1997Molecular and Cell Biology

    Collapse Overview 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025 Apr; 39(4):816-826. Ravi G, Richard S, Kumar S, Atrash S, Liedtke M, Kaur G, Derman B, Bergsagel PL, Mailankody S, McCarthy P, Shrestha A, Kelly LM, Ly T, Das S, Thorpe J, Maier A, Varun D, Navarro G, Burgess MR, Hege K, Koegel AK, Costa LJ. PMID: 39910285; PMCID: PMC11976278.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar; 101(3):557-569. Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. PMID: 34981142; PMCID: PMC9414073.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCTClinical Trials
    3. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 06 14; 131(24):2682-2697. An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. PMID: 29592892; PMCID: PMC6032890.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    4. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell. 2017 02 23; 168(5):817-829.e15. Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. PMID: 28215705; PMCID: PMC5541948.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimalsCells
    5. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313. Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. PMID: 28191887; PMCID: PMC5540325.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    6. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 2015 Jul 20; 4. Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K. PMID: 26193121; PMCID: PMC4569895.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    7. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014 Dec 18; 124(26):3947-55. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. PMID: 25361812; PMCID: PMC4271180.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    8. MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14876-81. Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL. PMID: 25271328; PMCID: PMC4205655.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    9. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 03; 6(304):ra105. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PMID: 24300897; PMCID: PMC4117477.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    10. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19466-71. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. PMID: 17164333; PMCID: PMC1698443.
      View in: PubMed   Mentions: 52     Fields:    Translation:AnimalsCells
    11. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal. 2006 Aug 11; 6:918-30. Burgess MR, Sawyers CL. PMID: 16906325; PMCID: PMC5917346.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    12. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005 Mar 01; 102(9):3395-400. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. PMID: 15705718; PMCID: PMC552942.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCells
    Michael's Networks
    Concepts (123)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.